| Literature DB >> 29181725 |
Anna Degiovanni1, Enrico Boggio1, Eleonora Prenna1, Chiara Sartori1, Federica De Vecchi1, Paolo N Marino2.
Abstract
BACKGROUND: Diastolic dysfunction promotes atrial fibrillation (AF) inducing left atrial (LA) remodeling, with chamber dilation and fibrosis. Predominance of LA phasic conduit (LAC) function should reflect not only chamber alterations but also underlying left ventricular (LV) filling impairment. Thus, LAC was tested as possible predictor of early AF relapse after electrical cardioversion (EC).Entities:
Keywords: Atrial fibrillation; Electrical cardioversion; Full-volume 3D echocardiography; Left atrial conduit function
Mesh:
Year: 2017 PMID: 29181725 PMCID: PMC5869942 DOI: 10.1007/s00392-017-1188-9
Source DB: PubMed Journal: Clin Res Cardiol ISSN: 1861-0684 Impact factor: 5.460
Patients’ clinical characteristics and pharmacological treatment
| Characteristics | Total pts (no. = 96) | SR (no. = 62) | AF (no. = 34) |
|---|---|---|---|
| Age (years) | 73 (67–77) | 72.5 (66.8–76.3) | 73 (66.8–78.3) |
| BMI (kg/m2) | 28.4 ± 3.89 | 28.4 (25.9–30.8) | 28.2 (25.5–31.3) |
| CHA2DS2VASc | 3 (2–4) | 3 (2–4) | 3 (2–4) |
| Sex (M/F) | 66/30 | 45/17 | 21/13 |
| Underlined cardiopathy (no. of pts) | |||
| Hypertensive | 55 | 37 | 18 |
| Hypertrophic | 1 | 1 | 0 |
| Post-ischaemic | 3 | 3 | 0 |
| Dilatative | 5 | 2 | 3 |
| Mild-reduced EF | 3 | 2 | 1 |
| Valvular | 4 | 3 | 1 |
| No other than AF | 25 | 17 | 8 |
| AF history duration (months)—unknown in 56 pts | 4.9 ± 2.9 | 5.0 ± 2.5 | 4.8 ± 2.1 |
| Oral medical treatment (no. of pts) | |||
| Amiodarone | 56 | 37 | 19 |
| Propafenone | 13 | 10 | 3 |
| Flecainide | 12 | 7 | 5 |
| Sotalol | 4 | 4 | 0 |
| Digoxin | 22 | 14 | 8 |
| Beta-blockers | |||
| Bisoprolol | 47 | 31 | 16 |
| Metoprolol | 4 | 4 | 0 |
| Carvedilol | 4 | 2 | 2 |
| Nebivolol | 7 | 3 | 4 |
| Atenolol | 4 | 4 | 0 |
| Ca++ channel blockers | |||
| Verapamil | 2 | 2 | 0 |
| Ace inhibitors | 31 | 22 | 9 |
| MRA | 20 | 13 | 7 |
| VKA | 74 | 52 | 22 |
| NOA | 22 | 10 | 12 |
| Comorbidities (no. of pts) | |||
| COPD | 6 | 1 | 5 |
| OSAS | 4 | 3 | 1 |
| CKD (GFR < 50 ml/min) | 14 | 9 | 5 |
| Metabolic disease | 61 | 39 | 22 |
| Current smoking | 6 | 3 | 3 |
| Bundle branch block | 9 | 7 | 2 |
| Hypertension | 80 | 52 | 28 |
| Diabetes | 19 | 12 | 7 |
AF atrial fibrillation, F female, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, EF ejection fraction, M male, MRA mineralocorticoid receptor antagonist, NOA new oral anticoagulants, OSAS obstructive sleep apnea syndrome, SR sinus rhythm, VKA Vitamin K antagonist
Fig. 1Dataset of echocardiographic acquisitions. Panel of different echocardiographic acquisitions with 2D and 3D probe
Post-cardioversion instrumental data for the entire patients’ population and after it has been divided according to 1-month recurrence of AF
| Parameters | Total pts | SR (no. = 62) | AF (no. = 34) |
|
|---|---|---|---|---|
| HR (beat/min) | 84.7 ± 19.0 | 80.0 [71.0–99.3] | 82.0 [70.0–95.5] | 0.583 |
| LA stress (g/cm2) | 129.9 ± 22.4 | 124.8 ± 21.6 | 139.2 ± 21.2 | 0.002 |
| Systolic blood pressure (mmHg) | 132.9 ± 15.1 | 133.8 ± 15.3 | 131.3 ± 14.9 | 0.455 |
| Diastolic blood pressure (mmHg) | 81.6 ± 10.1 | 81.3 ± 10.1 | 82.1 ± 10.2 | 0.723 |
| Pulse pressure (mmHg) | 51.4 ± 11.4 | 52.6 ± 11.9 | 49.2 ± 10.4 | 0.191 |
| LV EDV (ml) | 98.8 ± 26.5 | 96.6 ± 26.3 | 102.3 ± 26.7 | 0.344 |
| LV EF (%) | 51.7 ± 6.8 | 52.3 ± 6.3 | 50.7 ± 7.5 | 0.275 |
| LAV min (ml) | 52.2 ± 16.7 | 49.9 ± 16.6 | 56.4 ± 16.3 | 0.067 |
| LAV max (ml) | 65 ± 18.1 | 65.5 ± 18.8 | 64.1 ± 17.0 | 0.383 |
|
| 9.3 ± 3.8 | 7.43 (6.26–10.32) | 10.27 (8.27–12.0) | 0.012 |
|
| 10.1 ± 2.6 | 10.19 ± 2.60 | 9.85 ± 2.71 | 0.547 |
|
| 4.0 (3.0–5.0) | 4.0 (3.0–6.0) | 4.0 (3.0–5.0) | 0.084 |
| LA strain (%) | 19.2 ± 6.6 | 19.3 (15.0–22.7) | 17.6 (13.9–21.5) | 0.408 |
| LV strain (%) | − 14.4 ± 4.1 | − 14.30 ± 3.91 | − 14.60 ± 4.36 | 0.408 |
| Conduit (%) | 76.4 (68.2–81.8) | 72.6 (62.0–76.4) | 84.6 (79.8–89.5) | < 0.001 |
| Reservoir (%) | 23.6 (18.2–31.8) | 27.4 (23.6–38.0) | 15.4 (10.5–20.2) | < 0.001 |
| LA EF (%) | 20.2 ± 9.7 | 22.6 (18.7–24.5) | 11.8 (9.5–16.0) | < 0.001 |
| E (cm/s) | 88.6 ± 25.5 | 83.9 ± 23.8 | 97.2 ± 25.7 | 0.014 |
| A (cm/s) | 31 (25.0–43.0) | 32.0 (25.3–41.0) | 30.5 (25.0–43.8) | 0.455 |
|
| 2.8 ± 1.2 | 2.4 [1.8–3.2] | 3.1 (1.9–4.3) | 0.063 |
|
| 6.08 (6.02–6.22) | 6.05 (6.01–6.16) | 6.15 (6.07–6.25) | 0.012 |
|
| 8.9 (6.0–6.2) | 9.7 (4.1–5.3) | 4.4 (2.3–2.9) | 0.058 |
| LV (ml) capacitance30 | 108.2 ± 29.5 | 106.5 ± 29.5 | 111.2 ± 29.8 | 0.461 |
AF atrial fibrillation, BMI body mass index, EDV end–diastolic volume, EF ejection fraction, HR heart rate, LA left atrial, LA EF left atrial emptying fraction, LAV left atrial volume, LV left ventricle, Pts patients, SR sinus rhythm
Multiple logistic regression
| Independent variable | Coefficient | Standard error |
|
|---|---|---|---|
| Constant | − 14.49 | 11.19 | 0.196 |
| LA wall stress | − 0.004 | 0.032 | 0.891 |
|
| 0.264 | 0.178 | 0.138 |
| Conduit | 0.210 | 0.085 | 0.013 |
| LA EF | − 0.189 | 0.108 | 0.081 |
|
| − 0.168 | 1.108 | 0.880 |
LA left atrial, LA EF left atrial emptying fraction
Fig. 2ROC curve for the prediction of early arrhythmia recurrence. A conduit value of 79% of ventricular stroke volume can identify those patients that reverted to AF early after EC (ROC area 0.93, p < 0.001) with 90% sensitivity and 85% specificity